Stefani Spranger Explores the Absence of T Cells in Melanoma Subtypes

Stefani Spranger, PhD
Published: Tuesday, Nov 08, 2016



Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

At the 2016 Society for Melanoma Research (SMR) Congress, Spranger discussed her findings that upregulation of the WNT/beta-catenin pathway within the tumor cell mediates the exclusion of T cells from the microenvironment. This is because a subtype of dendritic cells (CD141-positive) must be present to recruit T cells back into the tumor.


Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

At the 2016 Society for Melanoma Research (SMR) Congress, Spranger discussed her findings that upregulation of the WNT/beta-catenin pathway within the tumor cell mediates the exclusion of T cells from the microenvironment. This is because a subtype of dendritic cells (CD141-positive) must be present to recruit T cells back into the tumor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x